CACNA1C and Behcet disease: Second, despite the relatively large neuroimaging sample, we were underpowered to examine dose-dependent effects of CACNA1C rs1006737 (AA vs. AG vs.GG) or to subgroup BD according to features such as BD subtype, symptomatic status, comorbidity, and/or treatment.